Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APG-157 With Bevacizumab for Recurrent High-Grade Glioma
NCT06011109Phase 2Active, not recruiting
- Sponsor
- Aveta Biomics
- Start
- Dec 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of APG-157 in glioma, glioblastoma multiforme (GBM), sponsored by Aveta Biomics. Started Dec 2023; status: active, not recruiting.
02
Drugs
APG-157
03
Conditions
gliomaglioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT06011109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06011109.